Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
T
T. Burrow
High Impact
Professor
Also affiliated: Cincinnati Children's Hospital Medical Center (2006–2018); Arkansas Children's Hospital (2018–2025); University of Miami (2020); Concordia University Irvine (1935); University of Arkansas Medical Center (2020); Lankenau Heart Institute (2017); Science Oxford (1957); Woodlands Hospital (1980); Christ University (1935); University of Cincinnati (2007–2012); University of Newcastle Australia (2012); University of Cincinnati Medical Center (2007–2010)
21 h-index
197 pubs
1,287 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
T. Burrow's research focuses on metabolic and genetic disorders, particularly Gaucher disease and lysosomal acid lipase deficiency. Burrow has investigated the efficacy of enzyme replacement therapies, including seblelipase alfa and eliglustat, in treating these conditions. Their work has also explored the underlying disease mechanisms, such as the role of complement in driving glucosylceramide accumulation and inflammation in Gaucher disease. This research has been supported by clinical trials and has contributed to understanding the impact of genetic mutations on disease progression, as seen in studies of de novo mutations in KIF1A causing encephalopathy.
Beyond specific genetic disorders, Burrow's research interests extend to diagnostic tools and their cost-effectiveness, particularly the use of whole exome sequencing in pediatric settings. They have also examined congenital anomalies, contributing to the characterization of conditions like choanal atresia. Burrow's scholarship metrics include an h-index of 21 with 197 total publications and 1,287 citations, designating them as a highly cited researcher. Collaborations include work with Carissa Rodriquez, Abhay A. Shukla, Hannah Barkley, and Alexis N. Roach at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 21
- Publications: 197
- Citations: 1,287
Positions
-
Professor 2023–presentUniversity of Arkansas for Medical Sciences Pediatrics Institutional directory
-
Associate Professor 2016–2023University of Arkansas for Medical Sciences Pediatrics ORCID
-
Assistant Professor 2009–2016Cincinnati Children's Hospital Medical Center Pediatrics ORCID
Selected Publications
-
Diagnostic Odyssey of Atypical Long‐Chain 3‐Hydroxyacyl‐ <scp>CoA</scp> Dehydrogenase Deficiency ( <scp>LCHADD</scp> ) Explained by Three Allelic Products From Two Pathogenic Variants (2026)
-
Central nervous system-symptomatic hyperammonemia following recombinant crisantaspase Pseudomonas fluorescens (2026)
-
Longitudinal Observation of Children with Achondroplasia: Findings from a Global Natural History Study (ACHieve) (2026)
-
Variants in BSN, encoding the presynaptic protein Bassoon, result in a distinct neurodevelopmental disorder with a broad phenotypic range (2025)
-
Correction: Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria (2025)
-
Variants in <i>BSN</i> , encoding the presynaptic protein Bassoon, result in a novel neurodevelopmental disorder with a broad phenotypic range (2025)
-
Neurodevelopmental delay, musculoskeletal disorders and dysmorphia associated with a novel pathogenic interstitial deletion of chromosome 10q21.1q21.3 (2025)
-
Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria (2024)
-
04145 Profound hypotonia in a newborn with Biallelic δ-Aminolevulinic Acid Dehydratase (ALAD) mutations (2024)
-
Design of a Phase 3 study of AAV-mediated gene transfer of ornithine transcarbamylase (OTC) in patients with late-onset OTC deficiency (2024)
-
DESIGN OF A PHASE 3 STUDY OF AAV-MEDIATED GENE TRANSFER OF ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY (2023)
-
Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource (2023)
-
Clinical insights from Wolman disease: Evaluating infantile hepatosplenomegaly (2022)
-
The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? (2022)
-
Mitochondrial Ultrastructural Defects in NDUFS3-Related Disorder (2021)
Collaboration Network
Top Collaborators
Priya Sunil Kishnani
Duke Medical Center (US)
7 shared publications
- The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Diagnosis and management of glycogen storage disease type IV, including adult polyglucosan body disease: A clinical practice resource
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Showing 5 of 7 shared publications
Pramod Kumar Mistry
Yale University (US)
4 shared publications
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Manisha Balwani
Icahn School of Medicine at Mount Sinai (US)
4 shared publications
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Barry E. Rosenbloom
Cedars-Sinai Medical Center (US)
4 shared publications
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Carlos Enrique Prada
Northwestern University (US)
4 shared publications
- The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
- Correlating liver stiffness with disease severity scoring system (DS3) values in Gaucher disease type 1 (GD1) patients
- Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States
Joel Charrow
Northwestern University (US)
3 shared publications
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Neal J. Weinreb
University of Miami (US)
3 shared publications
- The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
- Gaucher disease and SARS-CoV-2 infection: Emerging management challenges
Nicola Longo
University of Utah (US)
3 shared publications
- The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here?
- DESIGN OF A PHASE 3 STUDY OF AAV-MEDIATED GENE TRANSFER OF ORNITHINE TRANSCARBAMYLASE (OTC) IN PATIENTS WITH LATE-ONSET OTC DEFICIENCY
- Design of a Phase 3 study of AAV-mediated gene transfer of ornithine transcarbamylase (OTC) in patients with late-onset OTC deficiency
Hannah Barkley
University of Arkansas for Medical Sciences
3 shared publications
In database
- Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
- 04145 Profound hypotonia in a newborn with Biallelic δ-Aminolevulinic Acid Dehydratase (ALAD) mutations
- Correction: Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
Carissa Rodriquez
Arkansas Children's Hospital
3 shared publications
In database
- Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
- 04145 Profound hypotonia in a newborn with Biallelic δ-Aminolevulinic Acid Dehydratase (ALAD) mutations
- Correction: Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
Karl E. Anderson
The University of Texas Medical Branch at Galveston (US)
3 shared publications
- Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
- 04145 Profound hypotonia in a newborn with Biallelic δ-Aminolevulinic Acid Dehydratase (ALAD) mutations
- Correction: Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria
Hagit N. Baris
Technion – Israel Institute of Technology (IL)
2 shared publications
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Hadhami Ben Turkia
Hôpital La Rabta (TN)
2 shared publications
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Gerald F. Cox
Genesys (United States) (US)
2 shared publications
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Sumita Danda
Christian Medical College, Vellore (IN)
2 shared publications
- Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
Similar Researchers
Based on overlapping research topics
Elizabeth A. Sellars
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Genomics and Rare Diseases
Kirt E. Simmons
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Genomics and Rare Diseases
Health Sciences Research and Education
Yuri A. Zárate
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Genomics and Rare Diseases
Jennifer S. Guimbellot
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Health Sciences Research and Education
Vikki Stefans
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Genomics and Rare Diseases
R. DALEY GOFF
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Genomics and Rare Diseases